PSYK ETF
PSYK
New York Stock Exchange Arca- -
USD
- -
- -
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Sector
- Financial Services
- Industry
- Asset Management
- Address
- DE United States of America
- IPO Date
- Jan 31, 2022
- CIK
- 0001540305
- Similar Companies
- Business
- PSYK ETF (NYSEArca: PSYK) is an exchange-traded fund that seeks to track the performance, before fees and expenses, of the Enhanced Consciousness Index, a rules-based index comprising companies engaged in the research, development, production, or use of psychedelic-based pharmaceuticals and therapeutics for treating mental health conditions such as depression, anxiety, and PTSD, as well as neurology biopharmaceutical firms when fewer than 25 qualifying psychedelic companies exist; the index caps individual holdings at 10% weight based on float-adjusted market capitalization, with additional restrictions on large pharmaceutical firms deriving less than 25% revenue from psychedelics. Launched on January 31, 2022, and managed by Exchange Traded Concepts LLC with administration by U.S. Bancorp Fund Services, LLC, the fund targets global developed-market equities including U.S. and Canadian stocks or ADRs, up to a maximum of 35 holdings; it features a net expense ratio of 0.75%, assets under management of approximately $1.81 million, and a dividend yield around 0.85%. The ETF provides investors exposure to the emerging psychedelics industry segment, focusing on life sciences firms with significant business activities in psychedelic medicines. Exchange Traded Concepts announced the closure and liquidation of PSYK ETF, with trading ceasing on NYSE Arca on March 27, 2023, and final liquidation occurring around March 28, 2023, due to low assets and trading volume; shareholders received cash proceeds net of expenses, marking a significant operational termination within its brief lifespan. Prior to closure, the fund experienced quarterly index rebalances and benefited from inflows following the August 2022 shutdown of rival Defiance PSY ETF, though it maintained modest average daily volume of about 1,266 shares. No recent partnerships, funding rounds, acquisitions, or new product launches were reported for the ETF itself in 2024 or 2025.